Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome
This is a single-center, open-label, basket phase 2b trial that will enroll Down Syndrome
(DS) participants with at least one inflammatory skin condition (Atopic Dermatitis (AD)
and/or Alopecia Areata (AA)). Patients will receive Abrocitinib 100 mg daily for 12
weeks...
Age: 12 years - 66+
Gender: All
Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations
This is a multicenter screening study to characterize the prevalence of the KIT D816V
mutation in participants with suspected clonal mast cell disease.
Age: 18 years - 66+
Gender: All
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
A Phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy
and safety of paltusotine treatment vs placebo as well as the long-term safety of
paltusotine in adults with carcinoid syndrome due to well-differentiated neuroendocrine
tumors. ...
Age: 18 years - 66+
Gender: All
An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM)
The goal of this clinical trial is to evaluate the long-term safety and tolerability of
zagociguat in patients with MELAS who completed study medication treatment in the lead-in
study TIS6463-203. TIS6463-204 is evaluating zagociguat in an open-label extension study
...
Age: Birth - 66+
Gender: All
Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19
The study is conducted in New York, New York at The Cohen Center for Recovery from
Complex Chronic Illness at Mount Sinai.
This is an IND-exempt, off-label, multi-ascending, randomized, placebo-controlled
clinical trial of sirolimus (also known as rapamycin) in adu...
Age: 18 years - 66+
Gender: All
REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome
The purpose of this study is to evaluate the efficacy and safety of ION582 in children
and adults with Angelman syndrome caused by a deletion or mutation of the UBE3A gene.
Age: 2 - 50 years
Gender: All
Lumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
This will be a pilot multi-arm clinical trial investigating the feasibility of 6 weeks of Lumbrokinase (LK) as an intervention in three clinical cohorts:
Long Covid (LC)
Post-treatment Lyme disease syndrome (PTLDS)
Myalgic encephalomyelitis/chronic fatigue syndrome (ME...
Age: 18 years - 66+
Gender: All
Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
This is a phase 2, randomized, multiple-dose, placebo-controlled study designed to
evaluate the safety, efficacy, and pharmacokinetics (PK) of CSL889 (human hemopexin) when
given intravenously (IV) to adults and adolescents with sickle cell disease (SCD)
experiencing...
Age: 12 years - 66+
Gender: All
Immunologic Basis of Food Protein-Induced Enterocolitis Syndrome
This is a phase I multicenter clinical trial that aims to find the optimal dose for
conducting a novel low-dose, multi-day oral food challenge (OFC) protocol for diagnosing
food protein-induced enterocolitis syndrome (FPIES). Individuals ages 1-60 years with a
histor...
Age: 1 year - 60 years
Gender: All
A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment
The purpose of this study in children with Noonan syndrome is to evaluate the effect of 3
doses of vosoritide on growth as measured by AGV after 6 months of treatment. The
long-term efficacy and safety of vosoritide at the therapeutic dose will be evaluated up
to FAH...
Age: 3 - 11 years
Gender: All
JAG201 Gene Therapy Study in Children & Adults With SHANK3 Haploinsufficiency
This is a Phase 1/2, first in human, open-label, dose-escalation study to evaluate the safety, tolerability, and clinical activity of a single dose of JAG201 administered via intracerebroventricular (ICV) injection in pediatric and adult participants with SHANK3 haploin...
Age: 2 - 9 years
Gender: All
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
The purpose of this study is to assess Tacrolimus/Methotrexate/Ruxolitinib versus
Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in
Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell
Transplantation
Age: 18 years - 66+
Gender: All
tVNS in Long COVID-19
A prior open label study has shown that transcutaneous vagus nerve stimulation [tVNS] can
improve the health of some patients with postacute sequelae of SARS-CoV-2 infection
(PASC), severely affected enough to also fulfill criteria for myalgic encephalomyelitis /
chr...
Age: 21 - 70 years
Gender: All
A Prospective Research Investigation of Ischemia Using MCG
PRISM is a prospective, pilot research study that aims to systematically characterize the
usefulness of CardiAQ MCG, a bedside magnetocardiography device, in the evaluation of
myocardial ischemia and infarction status.
Age: 18 years - 66+
Gender: All
Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
Open label, multi-centre, Phase Ia/b adaptive design study with an initial 2-stage Dose
Escalation Phase followed by a Dose Expansion Phase.
Age: 18 years - 66+
Gender: All
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells).
The purpose of this study is to assess the safety of venetoclax in combination with
obinutuzumab or acalabrutinib in the treatment of CLL. Adverse events and change in
disease act...
Age: 18 years - 66+
Gender: All
RECOVER-SLEEP: Platform Protocol
The platform protocol is designed to be flexible so that it is suitable for a range of
study settings and intervention types. Therefore, the platform protocol provides a
general protocol structure that can be shared by multiple interventions and allows
comparative an...
Age: 18 years - 66+
Gender: All
Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy
This study is researching an experimental drug called linvoseltamab combined with another
drug called dupilumab. The study is looking at patients who have severe IgE-mediated food
allergy. If the patient has an allergy, the body's defense system (immune system)
overr...
Age: 18 - 50 years
Gender: All
Psychopharmacological Treatment of Emotional Distress
This is an inpatient four-arm randomized control trial comparing single drug clonazepam (S arm), a two-drug combination clonazepam/olanzapine (D arm), and a three-drug combination clonazepam/olanzapine/buprenorphine (T arm) with treatment as usual (TAU arm) in the treat...
Age: 18 years - 66+
Gender: All
MCG Discovery Study in Emergency Departments
This prospective discovery study is designed to demonstrate the feasibility of using an
unshielded, mobile MCG device in an Emergency Department (ED) setting. The main question
it aims to answer is whether interpretable data can be reliably collected as part of an
ED...
Age: 18 years - 66+
Gender: All